The Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid: Systematic Review and Meta-analysis
- 9 June 2021
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (10) , 1291-1302
Abstract
Background Mycophenolic acid (MPA) is among the most commonly prescribed medications for immunosuppression following organ transplantation. Highly variable MPA exposure and drug response are observed among individuals receiving the same dosage of the drug. Identification of candidate genes whose polymorphisms could be used to predict MPA exposure and clinical outcome is of clinical value. Objectives This study aimed to determine the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of MPA in humans by means of a systematic review and meta-analysis. Methods A systematic search was conducted on PubMed, EMBASE, Web of Sciences, Scopus, and the Cochrane Library databases. A meta-analysis was conducted to determine any associations between genetic polymorphisms and pharmacokinetic or pharmacodynamic parameters of MPA. Pooled-effect estimates were calculated by means of the random-effects model. Results A total of 37 studies involving 3844 individuals were included in the meta-analysis. Heterozygous carriers of the UGT1A9 -275T>A polymorphism were observed to have a significantly lower MPA exposure than wild-type individuals. Four single nucleotide polymorphisms (SNPs), namely UGT1A9 -2152C>T, UGT1A8 518C>G, UGT2B7 211G>T, and SLCO1B1 521T>C, were also significantly associated with altered MPA pharmacokinetics. However, none of the investigated SNPs, including SNPs in the IMPDH gene, were found to be associated with the clinical efficacy of MPA. The only SNP that was associated with adverse outcomes was SLCO1B3 344T>G. Conclusions The present systematic review and meta-analysis identified six SNPs that were significantly associated with pharmacokinetic variability or adverse effects of MPA. Our findings represent the basis for future research and clinical implications with regard to the role of pharmacogenetics in MPA pharmacokinetics and drug response.Keywords
Funding Information
- Faculty of Medicine, Chiang Mai University (047-2564)
- Health Systems Research Institute (64-075)
This publication has 78 references indexed in Scilit:
- The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individualsClinica Chimica Acta, 2012
- Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetilPharmacogenetics and Genomics, 2010
- Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomicsBritish Journal of Pharmacology, 2010
- Risk of diarrhoea in a long‐term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant alleleBritish Journal of Clinical Pharmacology, 2010
- Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant PatientsClinical Journal of the American Society of Nephrology, 2010
- The Role of Organic Anion–Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- An inosine 5′-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acidThe Pharmacogenomics Journal, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant RecipientsClinical Pharmacokinetics, 2007
- A haplotype map of the human genomeNature, 2005
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998